TG Therapeutics, Inc.
TGTX
$42.54
-$0.60-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 1,079.81% | 1,812.41% | 3,215.24% | -36.82% | -4.97% |
| Total Depreciation and Amortization | 76.60% | -13.24% | -51.55% | -74.21% | -72.67% |
| Total Amortization of Deferred Charges | -25.98% | -36.52% | -44.67% | -44.91% | -32.55% |
| Total Other Non-Cash Items | -626.45% | -746.71% | -865.95% | 66.26% | 28.89% |
| Change in Net Operating Assets | -42.16% | -77.99% | -272.27% | -174.07% | -143.21% |
| Cash from Operations | 77.14% | 38.86% | -149.49% | -187.18% | -400.88% |
| Capital Expenditure | -242.86% | -375.56% | -600.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 468.33% | 1,514.03% | 173.74% | 87.44% | 91.36% |
| Cash from Investing | 457.77% | 1,431.95% | 173.44% | 87.30% | 91.23% |
| Total Debt Issued | 205.40% | -- | -100.00% | -- | -- |
| Total Debt Repaid | -137.09% | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 143.57% | 65.32% | 197.38% | 115.90% | -98.05% |
| Repurchase of Common Stock | -1,143.76% | -941.55% | -4,451.21% | -2,175,700.00% | -1,488,200.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -192.24% | -- | 96.39% | -- | -- |
| Cash from Financing | 150.95% | -169.81% | -171.96% | 20,402.12% | 157.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 447.19% | -215.78% | -370.86% | 428.27% | 304.22% |